Moesin is an ERM family protein that connects the actin cytoskeleton to transmembrane receptors.
INTRODUCTION
Gliomas, or tumors with features of glial differentiation, account for more than 50% of all brain tumors (1) . Among these, glioblastoma (WHO grade IV) is the most aggressive and commonly occurring primary intracranial tumor in adults, with an average incidence of 4-5 per 100,000 persons per year. Glioblastoma either arises de novo or progresses over time from lower grade tumors. The median survival is 12 to 15 months, with survival rates of 20% and 5% at 2 and 5 years, respectively (2) . The conventional treatment consists of surgical resection followed by radiotherapy and adjuvant chemotherapy with temozolomide, an oral alkylating agent (3) . Some glioblastoma tumor cells express an enzyme called O-6-methylguanine-DNA methyltransferase (MGMT) that repairs the type of DNA damage induced by temozolomide, and tumors in which MGMT levels are elevated show a poor response to this chemotherapy (4). The relatively high incidence of glioblastoma, its resistance to treatment and the dismal patient prognosis rendered this tumor a forefront for the drug discovery efforts.
Ezrin, radixin, moesin (ERM) and neurofibromatosis type 2 (NF2) proteins form a distinct subfamily of cytoskeletal members, belonging to the larger family of Band 4.1 proteins (5). The ERM-NF2 proteins share a conserved structure, consisting in an amino (N)-terminal FERM domain, an extended α-helical intermediate region and an actin-binding carboxyl (C)-terminal region, the latter being modified in NF2. The amino acid identity between ezrin and radixin, moesin, or NF2 is 86%, 86% and 62%, respectively, in the FERM domain, and 63%, 60% and 25%, respectively, in the rest of the molecule. It is apparent that the homology within the FERM domain is higher than in the other regions, and indeed the ERM-NF2 proteins share common ligands that bind to two defined pockets in the FERM domain (6) . One pocket accommodates the juxtamembrane polybasic motif of some transmembrane receptors, such as CD44 and NEP/CD10, or a different consensus motif in ICAM2 and CD43 (7) (8) (9) (10) . A non-overalpping neighbouring pocket binds to the Na/H exchanger 3 regulatory factors (NHERF) 1 and 2 adaptor proteins (6) . The FERM domain pockets are also the binding site for the C-terminal self-association region of the ERM proteins (11) , and this head-to-tail interaction can be either intramolecular or intermolecular, resulting in "closed" monomers or in dimers, respectively. In the monomeric "closed" conformation, the binding sites for FERM ligands, as well as for actin, are masked, and the inactive ERM proteins are most likely localized in the cytoplasm (5, 12, 13) . At least two events have been reported to induce a molecular opening, phosphorylation of a conserved C-terminal Thr residue (Thr567/564/558 for ezrin/radixin/moesin, respectively) (14) , and binding of a phosphatidyl inositol-4,5-bisphosphate (PIP 2 ) molecule in yet another area of the FERM domain (15, 16) . In open conformation, the ERM proteins are able to function by connecting plasma membrane proteins to the actin cytoskeleton (7) .
The physiological roles of ERM proteins are related to the structuring of the cell cortex, being involved in cell differentiation and morphogenesis (7) . In cancer, except for NF2, which has been incontestably established as a tumor suppressor (17, 18) , the role of the other ERM proteins is not entirely clear. We show here that moesin is distinctively upregulated in glioblastoma and acts as an oncoprotein in this malignancy. The dissection of moesin's pro-oncogenic mechanism of action identified CD44, a hyaluronan transmembrane receptor and stem cell marker, as a transducer of signals upstream the Wnt/β-catenin pathway. Importantly, we show that this oncogenic pathway can be drugged by specifically targeting the interaction between moesin and CD44. 
MATERIALS AND METHODS
Human Tissue Specimens. Frozen glioma specimens classified as based on World Health Organization (WHO) criteria were previously described (19) . The paraffin-embedded human normal brain, grade II (oligodendroglioma, low grade astrocytoma, mixed oligoastrocytoma), grade III (anaplastic astrocytoma, anaplastic oligodendroglioma), and grade IV (glioblastoma) glioma tissue microarray (TMA) was also described (20, 21) .
Immunohistochemistry and immunoflorescence.
Immunohistochemistry and confocal immunofluorescence were performed as described (20, 21 ) (see also Supplemental Material).
Plasmids and small hairpin (sh)RNAs. Human moesin cDNA was obtained from Dr. Vijaya Ramesh (Addgene Inc., Cambridge, MA) and the constructs used are described in Supplemental Material.
Cell lines, glioblastoma stem cells (GSC), retroviral infections, proliferation and neurosphere formation assays. The glioblastoma cell lines LN229, LN18, LN308, LN373, LN428, U87-MG, D54, A172, MO59J and U251-MG were previously described (20) . The normal human astrocyte (NHA) cell line was obtained from Dr. TJ Liu, MD Anderson Cancer Center. Patient-derived GSC2, GSC11 and GSC23 were kindly provided by Drs. Howard Colman and Fred Lang, MD Anderson Cancer Center, and propagated as neurospheres, as described (22, 23) . All the cells lines were tested and authenticated (20) . Transfections and retroviral infections were described (24) . The MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) proliferation assay was performed as described (20) . The GSC neurosphere formation assays are detailed in Supplemental Material.
Moesin-CD44 inhibitors. An inhibitory peptide targeting the moesin interaction site on CD44 (CD44pep) was designed, SRRRCGQKKKLVINSGNGAV, and subsequently custom synthesized with amidated C-terminus (Biosynthesis, Lewisville, TX). The quinocarmycin analog DX-52-1 previously shown to bind ERM proteins and inhibit the interaction of radixin with CD44 (25, 26) For GSC neurosphere assays, the inhibitors were added at plating (day 0).
Orthotopic tumorigenicity assay. The orthotopic tumorigenicity assay was performed in SCID mice by inoculating 10 6 LN229 cells as described (19) .
Protein analysis and antibodies. Cell lysis, immunoprecipitation, immunoblotting and cellular fractionation were previously described (21) . Antibodies are listed in Supplemental Material.
Luciferase assay. TOP/FOP β-catenin luciferase reporter assays were performed as described (27) . 
RNA

RESULTS
Moesin is progressively increased in gliomas and behaves as an oncoprotein.
In order to analyze the expression of ERM-NF2 proteins in tumors of increasing malignant phenotype, we initially examined 17 glioma samples by Western blot (Fig.1A) . Distinctively, moesin showed a marked expression increase in glioblastoma compared to lower grade gliomas (Fig.1A) . NF2 had an opposite trend, confirming our previous observations (21) , whereas ezrin and radixin did not show significant differences (Fig.1B) . Exploration of the same samples for putative ERM ligands revealed increased CD44 expression and decreased NHERF1 expression in glioblastoma (Fig.1B) . Importantly, the CD44 and moesin expression patterns exhibited strong direct correlation (Fig.1B, lower graph) . The expression of the epidermal growth factor receptor (EGFR) and EGFRv3 constitutive active splice variant in a subset of the glioblastoma samples (Fig.1B, red arrow) confirmed the high grade of the tumors, but did not correlate with moesin expression. Subsequent immunohistochemistry analysis of a glioma TMA containing normal brain and grades II-IV gliomas, confirmed the gradual increase of moesin staining in gliomas of increasing severity (Fig.1C) . Additional expression analysis of a panel of 10 glioblastoma cell lines in comparison to a normal human astrocyte (NHA) cell line showed increased moesin levels in all glioblastoma lines and higher CD44 levels in the majority (Fig.1D ). These combined results indicate moesin and CD44 as glioma progression markers, with highly correlated expression levels.
To define the role of moesin as oncoprotein in glioma, we examined the effect of moesin overexpression on tumor cell growth. Stable overexpression of Myc-tagged moesin in NHA and LN229 cells that express lower levels of endogenous moesin than other glioblastoma cells increased cell proliferation relatively to vector control cells ( Fig.2A) . To compare moesin's growth-promoting effects to those of another ERM protein, we established stable Myc-tagged ezrin overexpressing cells ( Fig.2A) As established cell lines are less representative of human gliomas than primary tumor cells propagated as neurospheres that retain stem-cell characteristics such as self-renewal (28, 29), we examined the effect of moesin on two patient-derived primary GSC neurosphere lines (Fig.2C ).
Moesin overexpression significantly increased neurosphere size in both GSC2 and GSC23 and also the neurosphere self-renewal ability in GSC2. As a global measure of GSC growth, the differences in the total number of cells were quantified in an MTT assay (Fig.S1 ). As for cell lines, partial knockdown of moesin in GSC11, which express higher levels of endogenous moesin than other GSCs, did not significantly alter their proliferation (Fig.S2) . Collectively, these results showed that moesin has marked growth-promoting consequences on GSCs.
To confirm the proliferative effect of moesin overexpression in vivo, we used our previously described brain tumor model (19) . In this orthotopic model, the moesin-everexpressing LN229 cells were highly proliferative and induced rapidly developing tumors that significantly shortened the animal survival (Fig.2D ). These results relate moesin overexpression to a fast-proliferating glioma phenotype, characteristic for glioblastoma.
Moesin is constitutively phosphorylated in glioblastoma cells.
To investigate the mechanism underlying the specific effect of moesin on glioblastoma growth, we first analyzed the activation status and subcellular localization of ERM proteins. As We also investigated the ERM protein phosphorylation in cells with Myc-moesin overexpression, and noted that it increased, and corresponded to the membrane fraction of overexpressed moesin (Fig.3C) . Overall, these results indicate that moesin is the ERM protein preferentially phosphorylated in glioblastoma cells.
To appreciate the importance of ERM phosphorylation in glioma, the glioma TMA was examined by immunofluorescence with phospho-ERM antibody (Fig.3D) . Strong positivity was observed in close to 50% of glioblastoma samples, in contrast with mild positivity in 10-15% of lower grade gliomas. Both atypical glial and microvascular endothelial cells were P-ERM positive in glioblastoma (Fig.3D-inset) . These results revealed high levels of ERM phosphorylation, most likely of moesin, specifically present in glioblastoma samples, indicating an activated ERM state in tumors. Moesin enhances the expression of CD44 and competes with NF2 for CD44 binding.
In phosphorylated active conformation, ERM proteins interact with their ligands (Fig.3A) .
Since moesin levels paralleled CD44 levels in glioma samples (Fig.1A) , we examined the effect of moesin overexpression on CD44 expression. In LN229 cells, endogenous and overexpressed moesin co-localized with CD44 at plasma membrane microspike protrusions (Fig.4A) . At higher magnification, the co-localization was concentrated at the base of the microspikes and in discrete areas along these structures (Fig.S6) . Overexpressed moesin also enhanced CD44 expression in these cells (Fig.4A) . To quantify the latter effect, a time course mitogenic stimulation of LN229 cells with and without moesin overexpression showed marked increase of CD44 expression levels in moesin-overexpressing cells (Fig.4B ). As observed, in the absence of serum, CD44 expression was undetectable in LN229 cells (Fig.4B, upper panel) . Similarly, in GSCs growing in serum-free conditions, CD44 expression was undetectable, in contrast to that of four other neural stem cell markers investigated (Figs.4C and S7). Moesin overexpression considerably raised CD44 expression in both LN229 cells and GSCs (Fig.4B-C) and also Sox2 expression in GSCs (Fig.4C ), consistent with a shift towards a more undifferentiated and malignant phenotype.
An important aspect of the interaction between CD44 and ERM-NF2 proteins is that whereas ezrin have been reported to enhance CD44 growth signaling (30) , NF2 has been shown to repress it (31) . As in approximately 1/3 of glioblastoma tumors, NF2 expression is maintained at normal high levels (21), we examined the possibility of a competition between moesin, ezrin and NF2 for CD44 occupancy (Fig.4D) . Immunoprecipitation of CD44 from lysates of vector, Myc-moesin and Mycezrin cells, as well as from vector and moesin kndockdown cells, showed that moesin overexpression displaced NF2 and ezrin from CD44, whereas moesin depletion had an opposite effect (Fig.4D, graphs) . Ezrin overexpression displaced moesin and, to a lesser extent NF2, from CD44 . These results suggested that moesin overexpression has a double impact on CD44 signaling, first, by enhancing its expression, and second, by decreasing its occupancy for NF2.
The moesin-CD44 interaction constitutes a potential therapeutic target in glioblastoma.
To examine whether the oncogenic effect of moesin is mediated through the interaction with CD44, we treated cells overexpressing moesin with a CD44-derived peptide, CD44pep, known to strongly interact in vitro with the FERM domain of ERM proteins (9, 32) . At a concentration of 0.5 μM, CD44pep had no effect on the proliferation of control or Myc-moesin-overexpressing cells (Fig.5A, left graph) . Remarkably, at 10 μM, CD44pep specifically suppressed the proliferation of Myc-moesin-overexpressing cells to levels slightly under those of control cells (Fig.5A, right graph). This result indicated that the effects of moesin on proliferation are mediated through the interaction with CD44, and that this interaction can be specifically targeted for inhibition.
The DX-52-1 drug has been developed for melanoma treatment in the 1990s (33-35).
Fenteany's group has shown that DX-52-1 binds tightly to radixin and less to ezrin and moesin (25) , and is able to disrupt the interaction between radixin and CD44 (26) . Based on these observations, we treated vector-control and moesin-overexpressing cells with serial concentration of DX-52-1 (Fig. 5B) . A sharp and specific decline of moesin-overexpressing cell proliferation to control levels was apparent at 100 nM. Higher concentrations stopped proliferation in both control and moesinoverexpressing cells.
To facilitate a more rapid translation into the clinic, these results were confirmed in GSCs (Fig.5C-E) . Both inhibitors significantly reduced the cell growth of moesin-overexpressing neurospheres in 3-day-proliferation assays ( Fig.5C-E, left graphs) . Interestingly, the growth of vector-control GSCs, which do not express CD44, was unchanged, supporting inhibition specificity for the moesin-CD44 interaction. In 5-day-neurosphere-formation assays, the size of moesin- 
overexpressing neurospheres was reduced by both inhibitors to levels similar to vector neurospheres ( Fig.5C-E, right graphs) . The neurosphere count was not significantly changed (not shown), suggesting that moesin might increase self-renewal independently of CD44. Mechanistically, treatment with CD44pep decreased the levels of moesin, CD44 and Sox2 (Fig.5D) , implicating the stability of the moesin-CD44 complex as key regulator of GSC growth. Collectively, these experiments clearly showed that the oncogenic effects of moesin overexpression in glioblastoma, most likely through the interaction with CD44, could be targeted with therapeutic drugs.
Large-scale analysis identifies the Wnt/β-catenin pathway as specific signaling downstream of the moesin-CD44 interaction.
Signaling through CD44 has been previously investigated and downstream ERK and PI3K-Akt pathway activation or Hippo cascade inhibition were described (36) (37) (38) (39) (40) . Moesin overexpression in glioblastoma and NHA cells activated the PI3K-Akt, ERK and p38 MAPK pathways (Fig.6A ).
To gain a better insight on the signaling triggered by moesin in glioblastoma, we interrogated a transcription-target-microarray containing direct targets of transcription factors downstream of signaling pathways involved in tumor growth ( Fig.6B and Table S1 ). This profiling revealed that:
(1) growth and metastasis-promoting factors were upregulated by moesin, whereas the inhibitors of growth were generally not modified, and (2) Wnt/β-catenin, a major growth pathway not previously implicated downstream of CD44 signaling, was activated by moesin. The profiled PI3K-Akt, ERK, JNK, NF-κB or Hippo pathways were engaged at various extents, as determined by FOXO, AP1, NF-κB and YAP/TAZ target variations, respectively (Fig.6B) .
We confirmed the Wnt/β-catenin activation by showing that c-Jun, the highest activated transcription target from the large-scale analysis, was specifically upregulated in moesin- (Fig.6C) . We next used the luciferasereporter system with β-catenin-responsive (TOP) or mutated (FOP) elements and observed that β-catenin transcriptional activity was significantly elevated in moesin-overexpressing cells (Fig.6D) .
Importantly, this activation was abolished when moesin-overexpressing cells were treated with CD44pep (Fig.6D) , indicating that the moesin-CD44 interaction specifically triggers the activation of β-catenin transcriptional activity. We further examined the phosphorylation and intracellular localization of β-catenin. β-catenin phosphorylation on residue Ser552 by Akt has been shown to induce β-catenin nuclear translocation and transcriptional activation (41, 42) . This residue was phosphorylated by moesin more than by ezrin overexpression in LN229 cells (Fig.6E) . The fractionation and immunofluorescence analysis of moesin-overexpressing cells showed that a fraction of β-catenin translocated from the membrane to the nuclear compartment in these cells (Fig.6F) . Overall, this comprehensive analysis showed that moesin, through binding to CD44, induces β-catenin nuclear translocation and increased transcriptional activity, which can be inhibited by specifically targeting the moesin-CD44 interaction. 
DISCUSSION
Glioblastoma is one of the relatively frequent cancers with very poor prognosis due to its invasiveness, tumor heterogeneity and resistance to chemotherapy. Efforts are focused on characterizing the molecular signature of these tumors in order to diagnose them and define new targets amenable to therapy. Our previous studies have defined a network of interacting tumor suppressors specifically disrupted in glioblastoma that include NF2 and NHERF1 (19) (20) (21) .
Continuing this analysis with a comprehensive examination of the other three ERM-NF2 members, we found that the expression levels of moesin, but not of ezrin or radixin, are significantly upregulated in glioblastoma. Moesin could thus be used as reliable marker of grade IV glioblastoma, and we pursue an extensive marker validation analysis for diagnostic purposes.
The ERM proteins have been implicated in the motility of cells and different aspects of metastasis (7, 43) . We show here that moesin overexpression increases glioma cell growth, and this effect is translated in vivo by a significantly decreased animal survival due to massive tumor cell proliferation. Interestingly, moesin depletion did not consistently decrease proliferation, suggesting that moesin is an oncogenic protein when overexpressed, similarly to EGFR growth factor receptors, for example. A compensatory effect of ezrin in moesin-depleted cells and GSCs could also explain the lack of phenotype change (see also below). Analyzing the EGFR expression that is upregulated in roughly 40% of glioblastoma samples (44), we did not find a correlation with moesin levels that were consistently elevated in the majority of cases. In contrast, CD44, a transmembrane receptor that interacts directly with ERM-NF2 proteins, showed similar expression trend as moesin. This led us to hypothesize that the proliferative signals of moesin are dependent of its interaction with CD44.
The findings of specific phosphorylation of moesin in glioblastoma on the conserved Thr558 residue that dictates a permissive conformational state for interactions between the FERM domain and CD44 supported this model (Fig.7) .
CD44 is a hyaluronic acid receptor that has an intracellular tail with non-overlapping binding sites for ERM-NF2 and ankyrin (38) . Because all ERM-NF2 members bind to the same site but have opposite effects on CD44 signal transduction, it has been hypothesized that they may compete for CD44 binding depending on the cell proliferative status which would determine their activation by phosphorylation (38) . We brought evidence that moesin, ezrin and NF2 compete for CD44 binding in glioblastoma, suggesting that not only the cell proliferative status is important for selective CD44 occupancy by ERM-NF2 members but also the expression levels of the various ERM-NF2 proteins.
Accordingly, NF2 acts as a natural inhibitor of CD44 signaling, with effects proportional to its expression levels. In glioblastoma, its levels are undetectable or decreased in two-thirds of cases (21, 45) , favoring thus an enhanced signaling through complexes between CD44 and other ERM members. Interestingly, moesin is overexpressed in almost all glioblastoma cases, suggesting that its effect is not limited only to displacing the traces of NF2 from CD44. Indeed, it appears that moesin is required for sustaining a CD44 positive feedback loop, in which the signaling through CD44 augments CD44's own expression. ERK activation has been previously shown to enhance CD44 transcription (46) , and we have shown that serum stimulation of LN229 cells increases CD44 levels. CAN-12-1040 signaling network in which the kinase responsible for ERM phosphorylation has more specificity for moesin than for ezrin. Taken together, these observations suggest a model in which moesin is preferentially transcribed and phosphorylated in glioblastoma, with major activating consequences on CD44 signaling (Fig.7) .
CD44 does not have a catalytic activity and the mechanisms by which it signals relate to its interactions with receptor tyrosine kinases (RTKs), such as Met or the EGFR family (38) . Although several pathways have been described downstream CD44 co-receptor function (38), we profiled a transcription factor target RT-PCR microarray that included outputs of known pathways but also other pathways involved in proliferation but not previously described for CD44 signaling. Surprisingly, the Wnt/β-catenin pathway was prominently and specifically activated downstream of the moesin-CD44 interaction. A possible mechanism of activation of this pathway by CD44 could transit through the activation of the PI3K by CD44-associated RTKs, with subsequent phosphorylation of β-catenin by Akt on residue Ser552, which has been shown to direct β-catenin to the nucleus (41, 42) . In moesin overexpressing cells, all these modifications were present, strongly supporting this mechanism (Fig.7) . Other moesin-independent but converging influences on the activation of Wnt-β-catenin pathway could come from the loss of NHERF1, which has been shown to destabilize β-catenin from the membrane and facilitate its nuclear translocation (27) .
An extensive literature on glioma transcriptomes from public microarray databases is available (47) (48) (49) (50) (51) . To examine whether moesin upregulation in glioblastoma is due to increased gene transcription, we reviewed these studies and found that moesin is on the short list of genes with mRNA levels consistently elevated in glioblastoma versus anaplastic astrocytoma (48, 50) .
Moreover, moesin transcript is part of the signature that differentiates glioblastoma-rich from oligodendroglioma-rich groups (49) . mRNA glioblastoma subgroups have been also described, including the proneural subtype with better prognosis and the mesenchymal subtype with increased 
aggressiveness (47, 51) . Although moesin transcript was not part of the mesenchymal subtype, it is present on the list of 884 genes in TCGA Worst Prognosis Signature from the glioblastoma TCGA dataset (47) , suggesting that it is highly enriched in the poor-prognosis subsets of all glioblastoma subtypes. Similarly, CD44 expression, even if not present in the latter analysis, has been associated with poorer prognosis in a subset of glioblastoma (52, 53) . While deemed a stem cell marker, CD44
is not consistently expressed in GSC neurospheres (22, 53) . We hint that serum deprivation might underlie this. Importanly, moesin boosts CD44 expression in serum-deprived GSCs and also increases the expression of the neural stem cell marker Sox2, supporting a functional shift towards an aggressive stem-like phenotype in glioblastoma.
With the advent of personalized cancer therapy, the discovery of markers for disease staging, progression and response to therapy is front line. Although glioblastoma is a rapidly fatal disease, some patients benefit from temozolomide, whereas those with MGMT overexpression are poor responders (4). Since we found moesin as a glioma progression marker in conjunction with CD44, we also tested if it could constitute a therapeutic target. Although CD44 has been previously investigated as therapeutic target in various malignancies (54) , the options considered for its inhibition were either eliminating its expression by miRNAs or interfering with the binding of ligands to its extracellular domain by a variety of blocking antibodies and peptides (55, 56) . In this study, we show for the first time a new modality of efficient CD44 inhibition by disrupting its interaction with moesin (Fig.7) . In principle, NF2 is the natural inhibitor of this interaction, and we have previously shown that NF2 overexpression suppresses the proliferation of glioblastoma cells (21) . Replacing NF2 with a specific CD44 peptide induced a potent inhibition of cell proliferation, comparable to that achieved by NF2 overexpression (data not shown). Importantly, the DX-52-1 quinocarmycin analog that was shown to disrupt the binding between radixin and CD44 (26) principle that a drug can accomplish the same effect as the specific peptide. DX-52-1 has been previously used in a clinical trial that was interrupted because of high toxicity (33) . However, our data prompt to the design and/or high-throughput detection of new and less toxic compounds targeting the CD44-moesin interaction. These drugs could not only be beneficial in glioblastoma, but also in tumors with ezrin overexpression, such as osteosarcoma or rhabdomyosarcoma, or in tumors with NF2-inactivating mutations, such as meningiomas, schwannomas and mesotheliomas.
In conclusion, we described here moesin as a marker for glioma progression that induces oncogenic growth through a mechanism involving the interaction with CD44 and subsequent activation of a host of downstream signaling cascades, including the Wnt/β-catenin pathway. We described for the first time a new therapy target consisting of the moesin-CD44 interface, whose disruption represses both the proliferation and β-catenin-dependent signaling. This study adds moesin and CD44 on the map of relevant molecular changes in glioblastoma and provides a drugable target for glioblastoma therapy. 
